¼±Åà - È»ìǥŰ/¿£ÅÍŰ
´Ý±â - ESC
KMLE °Ë»ö
°Ë»ö ¼³Á¤
¿Â¶óÀÎ ÀÇÇмÀû
ÀÇÇпë¾î »çÀü
ÀÇÇоà¾î
ÀÇÇлçÀü
ÇÑ¿µ/¿µÇÑ»çÀü
¿µ¿µ»çÀü
»çÀÌÆ® ¼Ò°³
Àç°Ë»ö
"validity of clinical study"¿¡ ´ëÇÑ ´ëÇÑÀÇÇù ÀÇÇпë¾î ¼¼ºÎ °Ë»ö °á°úÀÔ´Ï´Ù
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
4
¿µ¹®
ÇѱÛ
follow-up study
ÃßÀûÁ¶»ç
family study
°¡Á·Á¶»ç
longitudinal study
ÃßÀû¿¬±¸
molecular genetic study
ºÐÀÚÀ¯ÀüÇа˻ç
neurophysiological study
½Å°æ»ý¸®ÇÐÀû°Ë»ç
observational study
°üÂû¿¬±¸
pilot study
¿¹ºñ¿¬±¸
population study
Àα¸Á¶»ç
preclinical study
ÀÓ»óÀü½ÃÇè, ÀüÀӻ󿬱¸
pressure flow study
¾Ð·Â¿ä·ù°Ë»ç
prospective cohort study
ÀüÇâÄÚȣƮ¿¬±¸
prospective study
ÀüÇ⿬±¸, °èȹ¿¬±¸
real time study
½Ç½Ã°£°Ë»ç
retrospective cohort study
ÈÄÇâÄÚȣƮ¿¬±¸
retrospective study
ÈÄÇ⿬±¸
ÀÌÀü
´ÙÀ½
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
4
¿µ¹®
ÇѱÛ
case-control study
(¢¡retrospective) ÈÄÇ⿬±¸, µÞ¹æÇ⿬±¸
cohort study
(¢¡prospective) °èȹ¿¬±¸, ÀüÇ⿬±¸, ¾Õ¹æÇ⿬±¸
cross-sectional study
´Ü¸éÁ¶»ç¿¬±¸
double-blind study
ÀÌÁ߸Ͱ˹ý
study design
¿¬±¸°èȹ
family study
°¡Á·Á¶»ç
feasibility study
°¡´É¼º¿¬±¸
first pass study
ÀÏÂ÷Åë°ú°Ë»ç
follow-up study
ÃßÀûÁ¶»ç
infection control study
°¨¿°°ü¸®Á¶»ç
intervening study
°³ÀÔ¿¬±¸
longitudinal study
ÃßÀû¿¬±¸
microbiologic study
¹Ì»ý¹°Çа˻ç
migrant study
ÀÌÁֹבּ¸
mixing study
È¥ÇÕ°Ë»ç
ÀÌÀü
´ÙÀ½
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
4
¿µ¹®
ÇѱÛ
clinical crown
ÀÓ»óÄ¡¾Æ¸Ó¸®
clinical crown
ÀÓ»óÄ¡°ü(¡öÍή).
clinical decision making
ÀÓ»óÀû(ÀÎ) °áÁ¤
clinical dementia rating scale (CDRS)
ÀÓ»óÀû Ä¡¸ÅÆò°¡(ìúßÉîÜ öÂØÜøÄʤ)ôµµ
clinical diabetes
ÀÓ»ó(Àû) ´ç´¢º´ (¡îÜÓØèñÜ»).
clinical diagnosis
ÀÓ»ó(Àû) Áø´Ü(¡òàÓ¨).
clinical effect
ÀÓ»ó(Àû) È¿°ú
clinical efficacy
ÀÓ»óÀûÀ¯È¿µµ, ÀÓ»óÀûÈ¿´É (À¯È¿¼º)
clinical finding
ÀÓ»ó(Àû) ¼Ò°ß
clinical hematology
ÀÓ»óÇ÷¾×ÇÐ(¡úìäûùÊ).
clinical hematology
ÀÓ»óÇ÷¾×ÇÐ(?Ì´Ëâ̰).
clinical immunology
ÀÓ»ó¸é¿ªÇÐ
clinical implication
ÀÓ¼ºÀû(ÀÎ) ¿µÇâ, °á°ú
clinical isolate
ÀÓ»óºÐ¸®ÁÖ
clinical laboratory
ÀÓ»ó°Ë»ç½Ç
ÀÌÀü
´ÙÀ½
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
4
¿µ¹®
ÇѱÛ
ÀÌÀü
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
4
¿µ¹®
ÇѱÛ
ÀÌÀü
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
0
ÆäÀÌÁö:
4
¿µ¹®
ÇѱÛ
ÀÌÀü
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
4
¿µ¹®
ÇѱÛ
ÀÌÀü
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
4
¿µ¹®
ÇѱÛ
ÀÌÀü
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
0
ÆäÀÌÁö:
4
¿µ¹®
ÇѱÛ
ÀÌÀü
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
4
¿µ¹®
ÇѱÛ
ÀÌÀü
ÅëÇÕ°Ë»ö ¿Ï·á
ÀÌÀü
´ÙÀ½